A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
CA 2558708 A1 · Owner: H. Lundbeck A/S · Inventors: Thomsen, Lars Lykke; Pedersen, Anders Gersel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Provided herein is a pharmaceutical composition comprising : (a) an effective amount of one, or more of acetylcholinesterase inhibitor(s) or a pharmaceutically effective salt thereof; and, (b) an effective amount of one or more NMDA-antagonist(s). Also provided is the use of the, above composition for the manufacture of a medicament for the treatment of mild cognitive, impairment or dementia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 8, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 8, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 8, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.